Effect of immune checkpoint inhibitors at different treatment time periods on prognosis of patients with extensive-stage small-cell lung cancer

文献类型： 外文期刊

第一作者： Mi, Song

作者： Mi, Song;Zhang, Jiandong;Mi, Song;Liu, Xin;Liang, Ning;Hu, Pingping;Zhang, Jiandong;Mi, Song;Liu, Xin;Liang, Ning;Hu, Pingping;Zhang, Jiandong;Yang, Yunxin;Tang, Shaotong;Sun, Jinyue;Liu, Chao;Ren, Qidong;Lu, Jihong

作者机构：

关键词： Extensive-stage small-cell lung cancer (ES-SCLC); Immunotherapy; Prognostication; Lines of treatment

期刊名称：CLINICAL & TRANSLATIONAL ONCOLOGY （ 影响因子：3.4； 五年影响因子：3.1 ）

ISSN： 1699-048X

年卷期： 2024 年

页码：

收录情况： SCI

摘要： Background The application of immune checkpoint inhibitors (ICIs) in treating patients with extensive-stage small-cell lung cancer (ES-SCLC) has brought us new hope, but the real-world outcome is relatively lacking. Our aim was to investigate the clinical use, efficacy, and survival benefit of ICIs in ES-SCLC from real-world data analysis. Methods A retrospective analysis of ES-SCLC patients was conducted between 2012 and 2022. Progression-free survival (PFS) and overall survival (OS) were assessed between groups to evaluate the value of ICIs at different lines of treatment. PFS1 was defined as the duration from initial therapy to disease progression or death. PFS2 was defined as the duration from the first disease progression to the second disease progression or death. Results One hundred and eighty patients with ES-SCLC were included. We performed landmark analysis, which showed that compared to the second-line and subsequent-lines ICIs-combined therapy group (2SL-ICIs) and non-ICIs group, the first-line ICIs-combined therapy group (1L-ICIs) prolonged OS and PFS1. There was a trend toward prolonged OS in the 2SL-ICIs group than in the non-ICIs group, but the significance threshold was not met (median OS 11.94 months vs. 11.10 months, P = 0.14). A longer PFS2 was present in the 2SL-ICIs group than in the non-ICIs group (median PFS2 4.13 months vs. 2.60 months, P < 0.001). Conclusion First-line ICIs plus chemotherapy should be applied in clinical practice. If patients did not use ICIs plus chemotherapy in first-line therapy, the use of ICIs in the second line or subsequent lines of treatment could prolong PFS2.

分类号：

  • 相关文献
作者其他论文 更多>>

微信小程序